Slice of Healthcare’s Post

✅ 🔬 Research can ONLY move forward with patient volunteers. Courageous patient participation has helped scientists answer some of the most pressing questions about pulmonary fibrosis — and they want to continue answering more! 💭 This month, we’re highlighting three trials that are actively recruiting for the following conditions: 🔹 Myositis associated interstitial lung disease 🔹 Idiopathic pulmonary fibrosis Join a clinical trial to help researchers find new and improved treatments for pulmonary fibrosis. Learn about current trial highlights and how you can find a trial! 📌 Get started at https://conta.cc/3WAfOx4

✅ 🔬 Research can ONLY move forward with patient volunteers. Courageous patient participation has helped scientists answer some of the most pressing questions about pulmonary fibrosis — and they want to continue answering more! 💭 This month, we’re highlighting three trials that are actively recruiting for the following conditions: 🔹 Myositis associated interstitial lung disease 🔹 Idiopathic pulmonary fibrosis Join a clinical trial to help researchers find new and improved treatments for pulmonary fibrosis. Learn about current trial highlights and how you can find a trial! 📌 Get started at https://conta.cc/3WAfOx4

✅ 🔬 Research can ONLY move forward with patient volunteers. Courageous patient participation has helped scientists answer some of the most pressing questions about pulmonary fibrosis — and they want to continue answering more! 💭 This month, we’re highlighting three trials that are actively recruiting for the following conditions: 🔹 Myositis associated interstitial lung disease 🔹 Idiopathic pulmonary fibrosis Join a clinical trial to help researchers find new and improved treatments for pulmonary fibrosis. Learn about current trial highlights and how you can find a trial! 📌 Get started at https://conta.cc/3WAfOx4

📢 Exciting News! Our latest research, titled "Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis" has just been published in the European Heart Journal! 🎉 In this IPDMA, we found that the incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding. Many thanks to all co-authors involved in this project: Delphine Douillet, Kim Luijken, Cecile Tromeur, Andrea Penaloza, Olivier Hugli, Drahomir Aujesky, Stefano Barco, Joseph R Bledsoe, Kyle Chang, Francis COUTURAUD, Paul den Exter, Carme Font, Menno Huisman, David Jimenez, Christopher Kabrhel, Jeffrey Kline, Prof.Dr.Stavros Konstantinides, Thijs van Mens, Remedios Otero, W Frank Peacock, Olivier Sanchez, William B Stubblefield, Luca Valerio, David R Vinson, Philip Wells, Maarten van Smeden, Pierre-Marie Roy, Erik Klok Read the full article here: https://lnkd.in/eJqBPr68 #Research #PulmonaryEmbolism #HomeTreatment #TriageTools #EuropeanHeartJournal

Sharing in this network our latest research on how a spatially-resolved single cell atlas of a human tissue could be useful in the clinical setting. Based on data collected in the Brazilian Amazon, our integrated approach examines longitudinal clinical parameters, blood biomarkers, and lung pathology in COVID-19 patients. By integrating clinical and blood biomarkers with post-mortem lung-specific signatures, we've identified predictors of disease progression. This knowledge opens avenues for more precise and effective treatments. #science #diseaseprediction #infectiousdiseases

Radiotherapy is effective for patients with early progressive Dupuytren's disease. It's so important not to overtreat patients who have either very early disease or where the contracture is too advanced. Watch the video below for my thoughts on this. #radiationtherapy #radiotherapy #radonc #medicine #healthcare  #dupuytrens #handsurgery #handtherapy

👁️ Exciting news from our portfolio company, Oculis! They announced positive Phase 2b RELIEF trial results for Licaminlimab/OCS-02, a breakthrough in treating Dry Eye Disease with precision medicine. -Significant efficacy improvements -TNFR1 biomarker patients showed a 7x higher symptom response and 5x higher sign response, proving the power of personalised treatment. These results will help them to accelerate Licaminlimab/OCS-02 development. Read the full article in the comments 👇 #Oculis #DryEyeDisease #PrecisionMedicine #HealthcareInnovation

When is the right time to begin radiotherapy for Dupuytren’s disease? Watch IORBC President Dr Richard Shaffer answer this question in a recorded conversation with Anna Schurer, Chairperson of the British Dupuytren’s Society. In the video Richard addresses 👇 ➡️ Monitoring the disease early on in the disease course ➡️ Ways to monitor disease progression at home ➡️ Based on disease progression, when is a person eligible for radiotherapy? To watch the video on the British Dupuytren's Society YouTube channel, please click: https://lnkd.in/e4GPTZgm #radiotherapy #dupuytrens #medicine

We are thrilled to be uniting with world-leading IgG4-RD experts for the upcoming Fifth International Symposium on IgG4-Related Disease from April 4-6. Previous symposium outcomes that have had a lasting impact on the IgG4-RD community include: ◾️ Naming the disease! ◾️ Establishing definitions for the pathology of this condition ◾️ Launching the first set of Classification Criteria for this condition ◾️ Formulating a worldwide consensus document about the approach to treatment While rare disease progress doesn’t happen overnight, huge strides have been made already in IgG4-RD simply by the act of bringing disease experts together. The achievement of a longstanding goal – the regulatory approval of new treatments – now appears within our grasp. Learn about the major insights shared at the upcoming Fifth International Symposium on IgG4-RD on Friday, April 26. On that day, John Stone MD, MPH from the Massachusetts General Hospital in Boston and Emanuel Della Torre from the Ospedale San Raffaele in Milan will be hosting a live Fireside Chat, reviewing key takeaways from the Symposium. #IgG4RD #IgG4relateddisease #raredisease Learn more about the Symposium here: https://lnkd.in/emFtz4nq

One of the largest health concerns is, arguably, cardiovascular disease. So, excited to be part of iCARE4CVD shaping the future of personalized CVD care and improving patient outcomes. iCARE4CVD, a consortium of 30+ partners, coordinated by Maastricht UMC+ and Novo Nordisk, anticipates delivering: 💡 Early diagnosis and classification into clinically meaningful subgroups 💡 Risk stratification defining urgency for intervention 💡 Prediction of individual treatment response 💡 Inclusion of outcomes based on patient perspectives I look forward to driving the development of meaningful digital biomarkers in a very well-positioned working group from academia and industry. Digital biomarkers are here to stay and will be an essential part of the transition towards proactive, remote, and personalized healthcare. Want to know more about iCARE4CVD? 👉 https://icare4cvd.eu/ Want to learn about the role of TNO in the consortium and how we approach digital biomarker development? 👉 https://lnkd.in/d7N6kn-M TNO gezond iCARE4CVD Annika van Rosmalen Andre Boorsma Tim van den Broek Kit Buurman Roderick Scherptong Douwe Atsma John Morales Negin Hajizadeh (MD, MPH) Benoit Tyl, MD FESC Iñaki Romero Marlo Verket Jennifer Meessen Hajar Ghaem Sigarchian Hans-Peter Brunner-La Rocca #cardiovasculardisease #personalizedmedicine #digitalbiomarkers